Loading…
← CockpitCompetitor Analysis › MEDCL.PA MedinCell SAOpen in the cockpit ↗

MedinCell SAMEDCL.PACompetitor analysis, valuation and peers

France · EUR·Health Care›Pharmaceuticals: Major
Momentum leader 81
Mkt cap
$1.09B
US dollars, full cap
Free float
88%
of shares outstanding
$/day
$2.73M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 10.3%
Hurdle
n/a
no reverse DCF
Next earnings
21 days
9 Dec 2026
Close · EUR€27.66
1D-0.2%
1W-7.2%
1M+1.6%
3M+11.2%
6M+3.7%
YTD+9.8%
1Y-2.1%
ATR %4.2%
52w lowhigh14.6% off high

What MedinCell does

Employees: 150

MedinCell at a glance

Size MedinCell (MEDCL.PA) is a France Health Care company (Pharmaceuticals: Major) with a market value of $1.09B, the 132nd largest of 206 France companies the cockpit tracks. Shares closed at €27.66 on 18 Nov 2026.

Performance Over six months the shares gained 3.7%, against -9.7% for the median peer and -2.1% for the France market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue fell 23.2% over the last twelve months (peer median -1.2%); the operating margin is -130.6% (peer median 8.9%).

Valuation It trades at 49.6× enterprise value to sales against a peer median of 2.9× (most expensive of 18).

Next results Next results expected around 9 Dec 2026 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026MEDCL.PA 104Peer median 93
Six months, rebased to 100: MedinCell against the median of its 20 peers (local-currency closes).

MedinCell financials

Reported figures in EUR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€19.5M€19.5M€25.4M€9.03M€9.89M
Revenue growth—-23%+181%-9%—
EBITDA-€23.7M-€23.7M-€11.2M-€22.2M-€26.2M
Net income-€31.3M-€31.3M-€18.4M-€25.0M-€32.0M
Free cash flow-€25.9M-€25.9M€18.4M-€13.8M-€26.0M
Capital expenditure€2.04M€2.04M€1.66M€1.19M€1.03M
Total debtn/a€57.4M€58.8M€59.0M€57.7M

Quarterly statements and history in the cockpit →

MedinCell competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%PYC600812OMERVETO300119237690VIYASH006280CMHC1952BLUEJET6007894547BSLN002737688513MEDCL.PA6-month return →1-month return →
Up and to the right = strong over both horizons. MedinCell is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×20×40×600812VETO237690VIYASHCMHC1952002550BLUEJET002737MEDCL.PARevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. MedinCell is the large dot.

MedinCell competitors and peer comparison

How MedinCell compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

MedinCell against its 20 peers (data as of 18 Nov 2026)
MeasureMEDCL.PAPeer medianRank in peer set
1-month return+1.6%-1.6%9th highest of 21
6-month return+3.7%-9.7%6th highest of 20
Distance from 52-week high-14.6%-29.8%5th highest of 21
Revenue growth (TTM)-23.2%-1.2%2nd lowest of 17
Operating margin-130.6%8.9%lowest of 18
EV / Sales49.6×2.9×most expensive of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%49.6×n/an/a
PYC Therapeutics PYC.AXAustralia$1.09B+29%n/an/an/an/an/a
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%2.4×1.0%-4.2%
Omeros OMERUnited States$1.08B+24%n/a-56%17.3×n/an/a
Vetoquinol VETO.PAFrance$1.10B+19%-1%15%1.5×-3.6%+4.2%
Tianjin Ringpu Bio-technology 300119.SZChina$1.11B-7%-9%11%2.3×4.9%+11.3%
ST Pharm 237690.KSSouth Korea$1.11B-51%+26%18%3.5×4.2%+21.7%
Viyash Scientific VIYASH.NSIndia$1.11B+3%+124%13%2.9×36.3%+20.4%
Symbiotec Pharmalab SYMBIOTEC.NSIndia$1.12Bn/an/an/an/an/an/a
GC Biopharma 006280.KSSouth Korea$1.12B-10%-3%4%1.2×n/an/a
Cosmo CMHC.SWSwitzerland$1.13B-30%-45%-13%8.2×n/an/a
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%3.0×n/an/a
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%4.2×3.4%-1.2%
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%8.1×40.8%+13.8%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%1.5×2.5%+6.5%
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%1.4×n/an/a
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%3.2×-5.6%+12.7%
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%1.7×-6.5%-7.7%
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%1.2×-0.3%+12.1%
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%4.2×4.4%+7.7%

Questions

Which companies are MedinCell's closest peers?
The cockpit's peer set: PYC Therapeutics (PYC.AX), North China Pharmaceutical (600812.SS), Omeros (OMER), Vetoquinol (VETO.PA), Tianjin Ringpu Bio-technology (300119.SZ), ST Pharm (237690.KS), Viyash Scientific (VIYASH.NS), Symbiotec Pharmalab (SYMBIOTEC.NS).
Is MedinCell expensive compared with its peers?
On ev / sales it trades at 49.6× against a peer median of 2.9×, most expensive of 18 in its peer set.
How has MedinCell stock performed?
Over six months to 18 Nov 2026 the shares returned +3.7% against -9.7% for the median peer; over one year -2.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.